Schlieren ZH – LimmaTech Biologics has secured the rights for the further development of a vaccine candidate from AbVacc. This is intended to protect against diseases caused by a specific bacterium. The Schlieren-based biotech company will also receive an exclusive option to acquire all worldwide rights.
The biotech company LimmaTech Biologics has signed a license agreement with the US company AbVacc, as detailed in a press release. Under the terms of the agreement, the company will further develop AbVacc's vaccine candidate LBT-SA7. This is intended to protect against diseases caused by the bacterium Staphylococcus aureus. In addition to skin infections, this also includes pneumonia, for example.
LimmaTech Biologics will initially conduct a Phase I clinical trial in the coming year. In addition, the company will receive an exclusive option to acquire all worldwide rights to the vaccine if the trial is successful.
"Infections caused by Staphylococcus aureus remain an urgent global medical priority for which there is currently no vaccine," emphasizes Franz-Werner Haas, CEO of LimmaTech Biologics, in the press release.
LimmaTech Biologics already has experience in the development of vaccines, including candidates related to Staphylococcus aureus. Haas sees the license agreement with AbVacc as a further milestone in the company's strategy of preventing untreatable microbial infections and positively influencing the rise in antimicrobial resistance.
LimmaTech Biologics is based in Schlieren and is a member of the Bio-Technopark Schlieren-Zurich. ce/ssp